Sigma-Tau HealthScience, Inc. v. United States

98 F. Supp. 3d 1365, 2015 CIT 102, 37 I.T.R.D. (BNA) 2153, 2015 Ct. Intl. Trade LEXIS 102, 2015 WL 5159064
United States Court of International Trade·Decided September 3, 2015·No. Slip Op. 15-102; Court 11-00093·Published·Cited by 2 cases

Opinion

OPINION AND ORDER

CARMAN, Senior Judge:

Before the Court are cross motions for summary judgment and Plaintiffs motion to strike certain expert testimony. See Pl.’s Mot. for Summ. J., ECF No. 64, and Mem. in Supp. of PL Sigma-Tau Health-Science, Ine.’s Mot. for Summ. J., ECF No. 64-1 (“PL’s MSJ”); Def.’s Cross-Mot. for Summ. J. and Def.’s Mem. in Supp. of Its Cross-Mot. for Summ. J., ECF No. 68 (“Def.’s MSJ”); and PL Sigma-Tau HealthScience, Inc.’s Reply in Supp. of its Mot. for Summary J./Opp’n to Gov’t’s Cross-Mot. and Mot. to Strike (“PL’s Reply”), ECF No. 69. Plaintiff Sigma-Tau HealthScience, Inc., a.k.a., Sigma-Tau HealthScience, LLC (“Sigma-Tau” or “Plaintiff’) moves that the two products at issue in this case — (1) Acetyl L-Carnitine Taurinate Hydrochloride with 1.5% Silica and (2) Glycine Propionyl L-Carnitine Hydrochloride USP with 1.5% Silica (hereinafter collectively “products at issue” or “L-Carnitine”) — are vitamins and properly classifiable as “vitamins” under the Harmonized Tariff Schedule of the United States (“HTSUS”) subheading 2936.29.50, which carries duty free treatment. Defendant U.S. Customs and Border Control *1368 (“Customs” or “Defendant”) cross-moves that the products at issue are not vitamins and properly classifiable as “quaternary ammonium salts” under HTSUS subheading 2923.90.00. For the reasons stated below, the products at issue are properly classified under HTSUS subheading 2923.90.00, and accordingly, Defendant’s motion for summary judgment is granted and Plaintiffs motion for summary judgment is denied. In addition, Plaintiffs motion to strike is denied.

BACKGROUND

This action originally involved fifteen entries of eight products imported by Plaintiff from its Italian parent company into JFK International Airport, New York, between 2008 and 2010. Def.’s MSJ at 1. The eight products are listed in Table A: 1

Product ID No._Product Chemical Name_

_1_Acetyl L-Carnitine Hydrochloride_:_

_2_Acetyl L-Carnitine Argüíate Dihydrochloride, USP with 1.5% Silica

_3_L-Carnitine Fumarate with 1.5% Silica ______

_4_Lysine L-Carnitine Fumarate Hydrochloride with 1.5% Silica_

_5_'L-Carnitine Inner Salt (also known as L-Carnitine Base)_

_6_L-Carnitine Hydrochloride_

7 Acetyl L-Carnitine Taurinate Hydrochloride with 1.5% Silica (trade _name L-Tauro)_

8 Gycine Propionyl L-Carnitine Hydrochloride, USP with 1.5% Silica _(trade name GlycoCarn)_

Compl. ¶ 13. Between 2009 and 2010, Customs liquidated and/or reliquidated Plaintiffs entries, classifying Products 1, 3, 5, and 6 under HTSUS subheading K2923.90.00, 2 which entered duty free, and Products 2, 4, 7, and 8 under HTSUS subheading 3824.90.92, 3 which carries a 5% duty. Def.’s MSJ at 2. The K designation in this subheading indicates duty-free status in accordance with HTSUS. General Note 13. 4 Id. at 2 n. 2. Plaintiff timely filed four protests against Defendant’s decision to classify Products 2, 4, 7 and 8 under HTSUS subheading 3824.90.92. Id. at 3. In its protests, Sigma-Tau argued that all of its products, even those that Customs classified as duty-free under HTSUS subheading K2923.90.90, should be classified under subheading 2936.29.50. Id.

Plaintiff applied for further review of Protest Number 4701-09-100897 regarding Products 1, 2, 7 and 8, which resulted in Customs issuing ruling letter [¶] H081683 on August 27, 2010. Id. In that ruling, Customs confirmed that Product 1 was a “nonaromatic quaternary ammonium salt compound provided for in the Pharmaceutical Appendix, and thus properly classifiable duty-free under HTSUS subheading K2923.90.00.” Id. However, Customs *1369 also confirmed that Products 2, 7 and 8 “were mixtures of nonaromatic compounds, and were thus properly classifiable under HTSUS subheading 3824.90.92.” Id. Customs denied two of Plaintiffs protests in part and denied two in full “in accordance with [¶] H081683.” Id.

Subsequently, in December 2011, Customs issued amended laboratory reports, which concluded: (i) Products 2, 7, and 8 are separate chemically defined organic compounds and thus are properly classifiable under HTSUS Chapter 29 as quaternary ammonium salts; and (ii) Product 2 was provided for in the Pharmaceutical Appendix. Id. at 3-4.

On February 10, 2014, the parties agreed that Products 1 through 6 are provided for in the Pharmaceutical Appendix and thus are properly classifiable as duty free under HTSUS subheading K2923.90.00. 5 Partial Stipulated J. and Order, ECF No. 37 (“Partial Stipulated Judgment”). Consequently, the two products remaining in controversy in this case are Product 7, which is known by its trade name as L-Tauro, and Product 8, which is known by its trade name as GlycoCarn. Def.’s MSJ at 4. Defendant explains that these two products could not be part of the K-designation stipulation because “neither taurinate nor glycine are provided for in the Pharmaceutical Appendix, [thus] these two products are not entitled to duty-free status with the K-designation.” Id. The Clerk of the Court severed entries 237-1325768-3 and 237-1329667-3 from this case, since those two entries entirely encompassed products no longer at issue, assigned them a new case number, and disposed of that case by joint stipulation. See Court No. 14-00042, Stipulated J.,

ECF No. 3.

On October 20, 2014, Plaintiff moved for Referral to Court-Annexed Mediation and Defendant opposed. See ECF Nos. 48, 49. The Court denied the Motion for Referral to Court-Annexed Mediation in Slip Opinion 14-133, ECF No. 52. On November 7, 2014, Plaintiff moved to compel certain discovery but subsequently withdrew its motion. See ECF Nos. 50, 62. In its motion for summary judgment, Plaintiff also requests as a part of its summary judgment remedy “costs, expenses, and attorney’s fees, as may be recoverable by law.” PL’s MSJ at 35. Defendant counters that such request “is premature and wholly inappropriate at this time.” Def.’s MSJ at 4 n. 6. In any case, Plaintiff has not filed for costs in the form of a Bill of Costs pursuant to USCIT Rule 54(d)(1) or for fees in the form of an application pursuant to the Equal Access to Justice Act, 28 U.S.C. § 2412(d), and USCIT Rule 54.1.

Free access — add to your briefcase to read the full text and ask questions with AI

Sigma-Tau HealthScience, Inc. v. United States, 98 F. Supp. 3d 1365, 2015 CIT 102, 37 I.T.R.D. (BNA) 2153, 2015 Ct. Intl. Trade LEXIS 102, 2015 WL 5159064 (cit 2015).

98 F. Supp. 3d 1365 (Sigma-Tau HealthScience, Inc. v. United States) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Sigma-Tau Healthscience, Inc. v. United States
838 F.3d 1272 (Federal Circuit, 2016)